drugset / Trial / NCT06635772
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
Timeline
- Start
- 2024-11
- Primary completion
- 2025-12-01
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10390 | Unknown | — | — |
| Comparator | Irbesartan | Small molecule | 300 mg | Oral |